Back

Brain-wide Genome Editing via STEP-RNPs for Treatment of Angelman Syndrome

Lu, X.; Xie, Y.; Bao, Y.; Yu, J.; Wang, Z.; Fan, J.; Sheu, W. C.; Long, G.; Tu, Z.; Tong, J.; Manquen, G.; Li, Y.; Katta, V.; Chow, R.; Chen, B.; Meng, Z.; Ma, Y.-h.; Qiu, C.; Chen, S.; Tsai, S.; Kumar, B. D.; Hendry, C. E.; Jiang, Y.-h.; Zhou, J.

2025-11-14 genetics
10.1101/2025.11.13.684643 bioRxiv
Show abstract

Brain-wide genome-editing remains a major hurdle for the treatment of neurogenetic disorders. Here, we report a non-viral, non-nanoparticle, chemical modification-based method, called Stimuli-Responsive Traceless Engineering Platform (STEP) that achieves highly efficient and brain-wide genome-editing of neurons in mice. Using cholesterol-based STEP as a lead, we show that a single administration of STEP-ribonucleoproteins (RNPs) results in functional genetic rescue with significant improvements across a battery of neurobehavioral domains in the Angelman syndrome (AS) mouse model. No significant off-target events or general toxicity effects are observed. STEP-RNPs are also highly efficient at editing human neurons and cortical brain organoids differentiated from AS patient-derived iPSCs. scRNA-seq analysis confirms functional genetic rescue via reactivation of Ube3a/UBE3A expression in human and mouse STEP-RNP-treated neuronal cells. Genome editing via STEP-RNPs has broad applications and the potential to treat many other neurogenetic disorders.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.